News for NTLA Stock

Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Intellia Announces Positive Two-Year Follow-Up Data from Ongoing Phase 1 Study of Nexiguran Ziclumeran (nex-z), in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy at Peripheral Nerve Society Annual Meeting Intellia Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Company Progress Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2025 Earnings and Company Updates Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Intellia Therapeutics Announces First Patient Dosed in the MAGNITUDE-2 Phase 3 Study of Nexiguran Ziclumeran (nex-z), a One-Time Gene Editing-Based Treatment for Transthyretin (ATTR) Amyloidosis with Polyneuropathy Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Nexiguran Ziclumeran (nex-z) for the Treatment of Transthyretin (ATTR) Amyloidosis with Cardiomyopathy Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Intellia Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Company Progress Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2024 Earnings and Company Updates Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Intellia Therapeutics Announces First Patient Dosed in the HAELO Phase 3 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema Intellia Therapeutics Announces Anticipated 2025 Milestones and Strategic Reorganization to Prioritize the Advancement of its Late-Stage Programs, NTLA-2002 and Nexiguran Ziclumeran (nex-z) Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Nexiguran Ziclumeran (nex-z) for the Treatment of Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression in Transthyretin (ATTR) Amyloidosis Intellia Therapeutics Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Intellia Therapeutics Announces Two Upcoming Investor Events in November 2024 Intellia Presents Positive Results from the Phase 2 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE) Intellia Therapeutics Announces New Date for Upcoming Investor Webcast Intellia Therapeutics Announces Initiation of HAELO Phase 3 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE) Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Intellia Therapeutics to Present New Clinical Data from the Phase 1 Study of nexiguran ziclumeran (nex-z) for the Treatment of Transthyretin (ATTR) Amyloidosis at the 2024 AHA Scientific Sessions Intellia Therapeutics to Present Data from the Phase 2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the 2024 ACAAI Annual Scientific Meeting Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Intellia Therapeutics Announces Second Quarter 2024 Financial Results and Highlights Recent Company Progress Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2024 Earnings and Company Updates Intellia Therapeutics Receives Authorization to Initiate Phase 1/2 Clinical Trial of NTLA-3001 for the Treatment of Alpha-1 Antitrypsin Deficiency Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Intellia Therapeutics Announces CFO Transition Intellia Announces Positive Clinical Proof-of-Concept Data for Redosing a CRISPR-Based Therapy with its Proprietary LNP-Based Delivery Platform Intellia Therapeutics to Present the First-Ever Clinical Data From Patients Redosed with an Investigational In Vivo CRISPR Gene Editing Therapy at the Peripheral Nerve Society Annual Meeting 2024 Intellia Therapeutics Names Brian Goff to its Board of Directors Intellia Therapeutics Announces Positive Long-Term Data from Ongoing Phase 1 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE) Intellia Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2024 Earnings and Company Updates Intellia Therapeutics to Present Updated Data from Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the EAACI Congress 2024 Intellia Therapeutics Announces First Patient Dosed in the Phase 3 MAGNITUDE Study of NTLA-2001 as a Single-Dose CRISPR-Based Treatment for Transthyretin Amyloidosis with Cardiomyopathy Intellia Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Company Progress Intellia Therapeutics and ReCode Therapeutics Announce Strategic Collaboration to Develop Novel Gene Editing Therapies for Cystic Fibrosis Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2023 Earnings and Company Updates Intellia Therapeutics Announces Publication of Positive Interim Phase 1 Data for NTLA-2002 in Patients with Hereditary Angioedema in the New England Journal of Medicine Intellia Therapeutics Highlights its Three-Year Strategic Priorities and Anticipated 2024 Key Milestones Intellia Therapeutics Receives European Union Orphan Drug Designation for NTLA-2002, an Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary Angioedema Intellia Therapeutics Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress Intellia Presents New Interim Data from the Ongoing Phase 1 Study of NTLA-2001 at the 4th International ATTR Amyloidosis Meeting Intellia Therapeutics to Present Updated Data from Ongoing Phase 1 Study of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis and Hold Conference Call to Discuss Third Quarter 2023 Earnings in November Intellia Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application to Initiate a Pivotal Phase 3 Trial of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis with Cardiomyopathy Intellia Therapeutics Receives Priority Medicines (PRIME) Designation From the European Medicines Agency for NTLA-2002, an Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary Angioedema Regeneron and Intellia Announce Expanded Research Collaboration to Develop CRISPR-Based Therapies for the Treatment of Neurological and Muscular Diseases Intellia Therapeutics Announces Second Quarter 2023 Financial Results and Highlights Recent Company Progress Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2023 Earnings and Company Updates Intellia Therapeutics Announces Retirement of Jean-François Formela, M.D. From its Board of Directors Intellia Therapeutics to Present Updated Interim Data from Ongoing Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the EAACI Hybrid Congress 2023 Intellia Therapeutics Announces First Quarter 2023 Financial Results and Highlights Recent Company Progress Intellia Therapeutics Releases 2023 Corporate Responsibility Report Highlighting the Advancement of its Environmental, Social & Governance (ESG) Priorities Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2023 Earnings and Company Updates Intellia Therapeutics Names Bill Chase to its Board of Directors Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to NTLA-2002 for the Treatment of Hereditary Angioedema Intellia Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for NTLA-2002, an In Vivo CRISPR-Based Investigational Therapy for the Treatment of Hereditary Angioedema (HAE) Intellia Therapeutics Announces Fourth Quarter and Full-Year 2022 Financial Results and Highlights Recent Company Progress Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2022 Earnings and Company Updates Intellia Therapeutics Awarded Innovation Passport in the United Kingdom for NTLA-2002, an Investigational Genome Editing Treatment for Hereditary Angioedema Intellia Therapeutics Highlights Strategic Priorities and Anticipated 2023 Key Milestones Intellia Therapeutics Announces Pricing of Public Offering of Common Stock Intellia Therapeutics Announces Proposed Public Offering of Common Stock Intellia Therapeutics Presents New Interim Data from First-in-Human Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the American College of Allergy, Asthma & Immunology 2022 Annual Scientific Meeting Intellia Presents Updated Interim Data from the Cardiomyopathy Arm of Ongoing Phase 1 Study of NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis at the American Heart Association Scientific Sessions 2022 Intellia Therapeutics Announces Third Quarter 2022 Financial Results and Highlights Recent Company Progress Intellia Therapeutics to Present Updated Interim Clinical Data from Ongoing Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema at the 2022 ACAAI Annual Scientific Meeting Intellia Therapeutics to Hold Conference Call to Discuss Third Quarter 2022 Earnings and Company Updates Intellia Therapeutics to Present at October Healthcare Investor Conferences Intellia and Regeneron Announce Initial Data from the Cardiomyopathy Arm of Ongoing Phase 1 Study of NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis Intellia and Regeneron Announce Initial Data from the Cardiomyopathy Arm of Ongoing Phase 1 Study of NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis Intellia Therapeutics Announces Positive Interim Clinical Data for its Second Systemically Delivered Investigational CRISPR Candidate, NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) Jeito Capital co-leads €75 million Series B financing in SparingVision Intellia Therapeutics Announces Upcoming Investor Event to Present Interim Clinical Data from Ongoing First-in-Human Studies of NTLA-2002 and NTLA-2001 on September 16, 2022 Intellia Therapeutics Receives U.S. FDA Orphan Drug Designation for NTLA-2002, an Investigational CRISPR Therapy for the Treatment of Hereditary Angioedema Intellia Therapeutics to Present Interim Clinical Data from Ongoing Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema at the 2022 Bradykinin Symposium Intellia Therapeutics Announces Second Quarter 2022 Financial Results and Highlights Recent Company Progress Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2022 Earnings and Company Updates Intellia and Regeneron Present Updated Interim Data from Phase 1 Study of CRISPR-based NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis Demonstrating that Deep Serum TTR Reductions Remained Durable After a Single Dose Intellia and Regeneron Present Updated Interim Data from Phase 1 Study of CRISPR-based NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis Demonstrating that Deep Serum TTR Reductions Remained Durable After a Single Dose Intellia Therapeutics to Present Updated Interim Clinical Data from Ongoing Phase 1 Study of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis at the International Liver Congress™ 2022 Intellia Therapeutics Announces First Quarter 2022 Financial Results and Highlights Recent Company Progress Intellia Therapeutics Names Muna Bhanji, R.Ph., to its Board of Directors Intellia Therapeutics Presents Preclinical Data Demonstrating Advancements in its CRISPR-Engineered Allogeneic Platform at the 2022 Keystone Symposia’s Precision Genome Engineering Conference Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2022 Earnings and Company Updates Intellia Therapeutics Receives U.S. FDA Orphan Drug Designation for NTLA-5001 for the Treatment of Acute Myeloid Leukemia  Intellia Therapeutics Announces First Patient Dosed in Phase 1/2a Clinical Trial of NTLA-5001 for the Treatment of Acute Myeloid Leukemia Intellia and Regeneron Announce Updated Phase 1 Data Demonstrating a Single Dose of NTLA-2001, Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis, Resulted in Rapid, Deep and Sustained Reduction in Disease-Causing Protein Intellia and Regeneron Announce Updated Phase 1 Data Demonstrating a Single Dose of NTLA-2001, an Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis, Resulted in Rapid, Deep and Sustained Reduction in Disease-Causing Protein Intellia Therapeutics Announces Fourth Quarter and Full-Year 2021 Financial Results and Highlights Recent Company Progress Intellia Therapeutics Enters Lease Agreement to Build Manufacturing Facility for its CRISPR-based Therapies Intellia Therapeutics Announces Two Upcoming Investor Events in February 2022 Intellia and ONK Therapeutics Announce Collaboration to Advance Allogeneic CRISPR-Edited NK Cell Therapies for the Treatment of Patients with Cancer Intellia Therapeutics Announces Acquisition of Rewrite Therapeutics Intellia Therapeutics Highlights Strategic Priorities and Anticipated Development Milestones for 2022 Intellia Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022 Intellia Therapeutics and Kyverna Therapeutics Announce Collaboration to Develop Next-Generation Allogeneic T-Cell Therapy for Autoimmune Diseases Intellia Therapeutics Appoints Derek Hicks as Chief Business Officer Intellia Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of NTLA-2002 for the Treatment of Hereditary Angioedema Intellia Therapeutics Announces Expansion of Ongoing Phase 1 Study of NTLA-2001 to Include Adults with Transthyretin Amyloidosis with Cardiomyopathy (ATTR-CM) Intellia Therapeutics to Highlight Ex Vivo Genome Editing and CRISPR/Cas9 Manufacturing Advances at 2021 American Society of Hematology (ASH) Annual Meeting Intellia Therapeutics Announces Third Quarter 2021 Financial Results and Highlights Recent Company Progress Intellia Therapeutics to Hold Conference Call to Discuss Third Quarter 2021 Earnings and Company Updates Intellia Therapeutics Receives U.S. FDA Orphan Drug Designation for NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis Intellia Therapeutics Presents Preclinical Data Demonstrating Advancements in its Broad Genome Editing Capabilities at the 2021 European Society of Gene & Cell Therapy Annual Congress Intellia Therapeutics and SparingVision Announce Strategic Collaboration to Develop Novel Ocular Therapies Using CRISPR/Cas9 Technology Intellia Therapeutics to Present New Preclinical Data Highlighting In Vivo and Ex Vivo Genome Editing Advances at 2021 European Society of Gene & Cell Therapy Annual Congress Intellia Therapeutics Receives Authorization to Initiate Phase 1/2 Clinical Trial of NTLA-2002 for the Treatment of Hereditary Angioedema Intellia Therapeutics to Present at Chardan’s 5th Annual Genetic Medicines Conference Intellia Therapeutics Announces U.S. FDA Acceptance of Investigational New Drug Application for NTLA-5001, its CRISPR/Cas9-Engineered TCR-T Cell Candidate for Acute Myeloid Leukemia Intellia Therapeutics to Present at September Healthcare Investor Conferences Intellia Therapeutics Announces Second Quarter 2021 Financial Results and Highlights Recent Company Progress Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2021 Earnings and Company Updates Intellia Therapeutics Announces Closing of $690 Million Public Offering of Common Stock Intellia Therapeutics Announces Pricing of Public Offering of Common Stock Intellia Therapeutics Announces Proposed Public Offering of Common Stock Intellia and Regeneron Announce Landmark Clinical Data Showing Deep Reduction in Disease-Causing Protein After Single Infusion of NTLA-2001, an Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis Intellia and Regeneron Announce Landmark Clinical Data Showing Deep Reduction in Disease-Causing Protein After Single Infusion of NTLA-2001, an Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis Intellia Therapeutics Names James Basta, J.D., as Executive Vice President, General Counsel and Corporate Secretary Blackstone Life Sciences, Cellex Cell Professionals, and Intellia Therapeutics Launch New CAR T-Cell Company Intellia Therapeutics to Present Interim Clinical Data from Ongoing Phase 1 Study of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis at the 2021 Peripheral Nerve Society Annual Meeting Intellia Therapeutics Announces First Quarter 2021 Financial Results Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2021 Earnings and Company Updates Intellia Therapeutics Announces Presentations at the 24th American Society of Gene and Cell Therapy Annual Meeting Intellia Therapeutics Names Georgia Keresty, Ph.D., M.P.H., to Board of Directors Intellia Therapeutics’ Investigational CRISPR Treatment NTLA-2001 Receives European Union Orphan Drug Designation for ATTR Amyloidosis Intellia Therapeutics Presents New Data on Expanded Cell Engineering Capabilities Utilizing Base Editors Intellia Therapeutics Presents Preclinical Proof of Concept for CRISPR-based In Vivo Editing of Bone Marrow at Keystone eSymposium Intellia Therapeutics Announces Fourth Quarter and Full-Year 2020 Financial Results Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2020 Earnings and Company Updates Intellia Therapeutics Highlights Strategic Priorities and Anticipated Development Milestones for 2021 Intellia Therapeutics Achieves Normal Human Alpha-1 Antitrypsin Protein Levels in Non-Human Primates Through Targeted Gene Insertion for the Treatment of AAT Deficiency Intellia Therapeutics Presents New Preclinical Data Supporting Its CRISPR/Cas9-Engineered TCR-T Cell Treatment for Acute Myeloid Leukemia at the 62nd ASH Annual Meeting Intellia Therapeutics Announces Closing of $201 Million Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares Intellia Therapeutics Announces Pricing of Public Offering of Common Stock Intellia Therapeutics Announces Proposed Public Offering of Common Stock Intellia Therapeutics Receives Grant to Develop Curative CRISPR/Cas9 In Vivo Sickle Cell Disease Treatments Intellia Therapeutics Doses First Patient in Landmark CRISPR/Cas9 Clinical Trial of NTLA-2001 for the Treatment of Transthyretin Amyloidosis Intellia Therapeutics Announces Third Quarter 2020 Financial Results Intellia Therapeutics to Hold Conference Call to Discuss Third Quarter 2020 Earnings and Company Updates Intellia Therapeutics Receives Authorization to Initiate Phase 1 Clinical Trial of NTLA-2001 for Transthyretin Amyloidosis (ATTR) Intellia Therapeutics Congratulates Co-Founder Jennifer Doudna On Winning the 2020 Nobel Prize in Chemistry for Inventing the Revolutionary CRISPR/Cas9 Genome Editing Technology Intellia Therapeutics Names John F. Crowley to Board of Directors Intellia Therapeutics to Present at Baird’s 2020 Virtual Global Healthcare Conference Intellia Therapeutics Announces Second Quarter 2020 Financial Results Intellia Therapeutics Announces First Quarter 2020 Financial Results Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2020 Earnings and Company Updates Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2020 Earnings and Company Updates Intellia Therapeutics Announces Pricing of Public Offering of Common Stock Intellia Therapeutics Reports Progress on CRISPR/Cas9 AML Cancer Therapy Using Proprietary Cell Engineering Process at the 23rd Annual Meeting of the American Society of Gene and Cell Therapy Intellia Therapeutics Names David Lebwohl, M.D., Chief Medical Officer Intellia Therapeutics to Present New Preclinical Data from Its CRISPR/Cas9 Programs at the 23rd Annual Meeting of the American Society of Gene and Cell Therapy Intellia Therapeutics Announces Closing of $115 Million Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares Intellia Therapeutics Announces Proposed Public Offering of Common Stock